AI clinical healthcare company Sensyne Health has entered into a strategic research agreement with an NHS trust to use AI to analyse genetic data to help find new treatments and develop medical research.
Formerly known as Drayson Health, Sensyne’s deal with Oxford University Hospitals NHS Foundation Trust (OUH) builds on an existing five-year partnership the organisations forged last year that saw Sensyne raise £10m for the development of digital health products.
Under the new deal, the technology company will use AI to analyse consented and anonymised genetic data, comprising diagnostic genetic tests and whole genome sequences.
Data the trust has produced over the past five years and information it will create over the next ten years will be analysed.
OUH will receive £5m in equity in Sensyne Health and benefit from royalties arising from any discoveries, the companies said.
Lord Paul Drayson, Sensyne Health chief executive, said: ‘Sensyne Health is developing world-leading capability in the use of clinical AI to analyse anonymised patient data. This new agreement, enabling the analysis of linked genotypic and phenotypic data, will further enhance our ability to make new discoveries and develop new treatments.’
Dr Brumo Holthof, OUH chief executive, added: ‘Oxford University Hospitals is one of the digital centres of excellence in the NHS. Because of our digital investments, we now have a unique database that will grow in size over time and this strategic research agreement will allow us to find new ways of treating our patients.’
Sensyne Health is based at the University of Oxford’s Old Road Campus.